Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 8Terminated 4Recruiting 4Active not recruiting 3Unknown 2No longer available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Dermatologic 39Thoracic 5Gastrointestinal 4Head & Neck 3Genitourinary 3NET 2Gynecologic 2Endocrine 2Breast 2Sarcoma 1Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Colorectal Neoplasms 878Pancreatic Neoplasms 572Carcinoma, Hepatocellular 542Stomach Neoplasms 512Esophageal Neoplasms 312Rectal Neoplasms 280Colonic Neoplasms 254Breast Neoplasms 203Neoplasms 201Liver Neoplasms 187Lung Neoplasms 174Carcinoma, Non-Small-Cell Lung 174Cholangiocarcinoma 153Ovarian Neoplasms 141Neoplasm Metastasis 135Gastrointestinal Neoplasms 133Esophageal Squamous Cell Carcinoma 130Melanoma 103Prostatic Neoplasms 98Biliary Tract Neoplasms 95Endometrial Neoplasms 83Uterine Cervical Neoplasms 79Head and Neck Neoplasms 72Squamous Cell Carcinoma of Head and Neck 69Carcinoma, Renal Cell 58Sarcoma 54Adenocarcinoma Of Esophagus 54Urinary Bladder Neoplasms 53Anus Neoplasms 52Triple Negative Breast Neoplasms 48

Interventions

pembrolizumab 1binimetinib 1Protein Kinase C 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Uveal Melanoma × Gastrointestinal × Clear all
NCT04792463 2026-03-09

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Ohio State University

Recruiting
500 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Cholangiocarcinoma

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

IDEAYA Biosciences

Phase 1/2 Recruiting
336 enrolled
DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT04130516 2025-12-18

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Linnaeus Therapeutics, Inc.

Phase 1/2 Recruiting
200 enrolled
DermatologicGastrointestinalThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT06805825 2025-09-23

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Novelty Nobility, Inc.

Phase 1 Recruiting
67 enrolled
DermatologicEndocrineGastrointestinalGenitourinaryNETSarcomaThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Adenoid Cystic, Piebaldism, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡